Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
DRUG
Upturn stock ratingUpturn stock rating

Bright Minds Biosciences Inc (DRUG)

Upturn stock ratingUpturn stock rating
$26.11
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: DRUG (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $94.81

1 Year Target Price $94.81

Analysts Price Target For last 52 week
$94.81Target price
Low$0.93
Current$26.11
high$79.02

Analysis of Past Performance

Type Stock
Historic Profit 1755.76%
Avg. Invested days 45
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 172.77M USD
Price to earnings Ratio -
1Y Target Price 94.81
Price to earnings Ratio -
1Y Target Price 94.81
Volume (30-day avg) 6
Beta 0.45
52 Weeks Range 0.93 - 79.02
Updated Date 06/29/2025
52 Weeks Range 0.93 - 79.02
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.4

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -10.57%
Return on Equity (TTM) -11.21%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 133275414
Price to Sales(TTM) -
Enterprise Value 133275414
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.07
Shares Outstanding 7083240
Shares Floating 2983319
Shares Outstanding 7083240
Shares Floating 2983319
Percent Insiders 22.55
Percent Institutions 74.12

Analyst Ratings

Rating 3
Target Price 94.81
Buy 2
Strong Buy 4
Buy 2
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Bright Minds Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Bright Minds Biosciences Inc. is a biotechnology company focused on developing novel drugs for the treatment of neuropsychiatric disorders, epilepsy, and pain. Founded in 2017, they have focused on developing selective 5-HT2C agonists. They went public via reverse merger in 2020.

business area logo Core Business Areas

  • Drug Development: Focuses on developing novel therapies for treating various central nervous system (CNS) disorders.

leadership logo Leadership and Structure

The leadership team consists of seasoned biotechnology executives and scientists. The organizational structure is typical of a biotech company with research, development, and administrative departments.

Top Products and Market Share

overview logo Key Offerings

  • BMB-101: A selective 5-HT2C agonist being developed for Dravet syndrome. It is in clinical trials. Competitors include existing anti-epileptic drugs from companies like GW Pharmaceuticals (now Jazz Pharmaceuticals) (JAZZ) and others developing novel therapies.
  • BMB-202: A selective 5-HT2C agonist being developed for treatment resistant depression. It is in preclinical stages. Competitors include SSRIs, SNRIs, and novel therapies developed by companies like Axsome Therapeutics (AXSM).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly the CNS therapeutic area, is characterized by high R&D costs, stringent regulatory requirements, and a significant unmet medical need. There is increasing interest in novel therapies for epilepsy, depression, and pain.

Positioning

Bright Minds is positioned as a drug discovery and development company focused on specific 5-HT2C receptor targets. Their competitive advantage lies in their selective agonists.

Total Addressable Market (TAM)

The TAM for CNS therapeutics is estimated to be hundreds of billions of dollars. Bright Minds is targeting specific subsegments within that TAM such as Dravet Syndrome and Treatment Resistant Depression, which represent significant market opportunities.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates targeting 5-HT2C receptor
  • Experienced leadership team
  • Focus on unmet medical needs

Weaknesses

  • Early-stage drug development
  • Limited financial resources
  • Dependence on successful clinical trials

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established pharmaceutical companies

Competitors and Market Share

competitor logo Key Competitors

  • Jazz Pharmaceuticals (JAZZ)
  • Axsome Therapeutics (AXSM)

Competitive Landscape

Bright Minds faces competition from established pharmaceutical companies with greater resources and experience. Their advantage lies in their novel drug candidates.

Growth Trajectory and Initiatives

Historical Growth: Growth is dependent on advancing drug candidates through clinical trials.

Future Projections: Future growth depends on the success of their clinical programs and potential partnerships.

Recent Initiatives: Advancing BMB-101 into later-stage clinical trials; preclinical research on BMB-202.

Summary

Bright Minds Biosciences is an early-stage biotech company focused on developing novel CNS therapies. Success hinges on positive clinical trial outcomes and securing partnerships. The company faces significant risks related to drug development and competition from larger pharmaceutical firms. Funding and cash management are crucial for their survival and progress. Their novel approach, if successful, could be a major strength.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports (where available)

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share figures are estimates based on available information and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bright Minds Biosciences Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2021-03-22
Co-Founder, CEO, President & Director Mr. Ian McDonald
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.